Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giloralimab + mFFX +/- Budigalimab in Metastatic Pancreatic Cancer
NCT04807972Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- May 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, randomised, open-label trial of giloralimab in pancreatic adenocarcinoma (PDAC), sponsored by AbbVie Inc. Primary endpoints: Percentage of participants experiencing Adverse Events up to 6 months, Number of Participants with Potentially Clinically Significant (PCS) Laboratory Values up to 6 months and 2 more. Started May 2021; status: terminated.
02
Drugs
giloralimab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04807972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04807972.